Rachel C Jankowitz
Overview
Explore the profile of Rachel C Jankowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oesterreich S, Pate L, Lee A, Chen F, Jankowitz R, Mukhtar R, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):61.
PMID: 39033157
There is growing awareness of the unique etiology, biology, and clinical presentation of invasive lobular breast cancer (ILC), but additional research is needed to ensure translation of findings into management...
2.
Gradishar W, Moran M, Abraham J, Abramson V, Aft R, Agnese D, et al.
J Natl Compr Canc Netw
. 2024 Jul;
22(5):331-357.
PMID: 39019058
Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations...
3.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley D, Isakoff S, et al.
J Clin Oncol
. 2024 Jun;
42(31):3652-3665.
PMID: 38935923
Purpose: Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet...
4.
Jacobs S, Wang Y, Abraham J, Feng H, Montero A, Lipchik C, et al.
Breast Cancer Res
. 2024 May;
26(1):83.
PMID: 38790033
No abstract available.
5.
Jacobs S, Wang Y, Abraham J, Feng H, Montero A, Lipchik C, et al.
Breast Cancer Res
. 2024 Apr;
26(1):69.
PMID: 38650031
Background: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA...
6.
Van Baelen K, Van Cauwenberge J, Maetens M, Beck G, Camden A, Chase M, et al.
NPJ Breast Cancer
. 2024 Mar;
10(1):23.
PMID: 38509112
Invasive lobular breast cancer (ILC) differs from invasive breast cancer of no special type in many ways. Evidence on treatment efficacy for ILC is, however, lacking. We studied the degree...
7.
Sanft T, Wong J, ONeal B, Siuliukina N, Jankowitz R, Pegram M, et al.
J Natl Compr Canc Netw
. 2024 Mar;
22(2):99-107.
PMID: 38437792
Background: The Breast Cancer Index (BCI) test assay provides an individualized risk of late distant recurrence (5-10 years) and predicts the likelihood of benefitting from extended endocrine therapy (EET) in...
8.
Rothschild H, Jo Chien A, Jankowitz R, Magbanua M, Mouabbi J, Shatsky R, et al.
J Clin Transl Sci
. 2023 Oct;
7(1):e202.
PMID: 37830005
[This corrects the article DOI: 10.1017/cts.2023.142.].
9.
Lenz L, Neff C, Solimeno C, Cogan E, Abramson V, Boughey J, et al.
Breast Cancer Res Treat
. 2023 Aug;
202(1):191-201.
PMID: 37589839
Purpose: A 3-biomarker homologous recombination deficiency (HRD) score is a key component of a currently FDA-approved companion diagnostic assay to identify HRD in patients with ovarian cancer using a threshold...
10.
Manik R, Grady C, Elmore L, Fieber J, Freedman G, Jankowitz R, et al.
Ann Surg Oncol
. 2023 Jul;
30(11):6506-6515.
PMID: 37460741
Introduction: Given the potential impact of increasingly effective neoadjuvant chemotherapy (NACT) on post-mastectomy radiotherapy (PMRT) recommendations, we examined temporal trends in post-NACT PMRT for cT3 breast cancer. Methods: We identified...